EFM
MLYS icon

E Fund Management’s Mineralys Therapeutics MLYS Stock Holding History

E Fund Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Sell
11,025
-837
-7% -$23K 0.01% 381
2026
Q1 		$321K Buy
+11,862
New +$348K 0.01% 377

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

E Fund Management's MLYS Position: Q2 2026 in Review

E Fund Management reduced its Mineralys Therapeutics (MLYS) stake by 7.1% in Q2 2026, selling an estimated $23K and leaving 11,025 shares worth $297K. The position accounts for 0.01% of the portfolio, ranked #381.

E Fund Management first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. The position peaked at $321K in Q1 2026. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • E Fund Management held 11,025 shares of Mineralys Therapeutics worth $297K as of Q2 2026.
  • E Fund Management sold 837 Mineralys Therapeutics shares in Q2 2026, an estimated $23K.
  • Mineralys Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #381 holding.
  • E Fund Management first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • E Fund Management's Mineralys Therapeutics position peaked at $321K in Q1 2026.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.